Compromission de la masse osseuse et de la motricité chez des malades traités par blocage androgénique

Therapeutic androgen suppression induces hypogonadism with effects on the patient’s locomotor system. We tried to verify these effects on a group of patients with prostate cancer presenting a prolonged life expectancy. Thirty six patients treated by radical prostatectomy (mean PSA: 7.2±1.3 ng/ml) had stage pT3 cancer in 24 cases and pT2c in 12 cases. The first group was treated by radiotherapy and androgen suppression and the second group was treated by androgen suppression alone after surgery. After 24–36 months (mean=28.4 months), staging was performed by CT scan, bone scintigraphy, PSA and testosterone assays, and bone densitometry. An identical assessment was repeated an average of 53.1 months after starting treatment. Staging never demonstrated disease recurrence; PSA was between 0.01 and 0.4 ng/ml (mean: 0.11 ± 0.96 ng/ml) and the mean plasma testosterone was 0.4 ng/ml. The first bone densitometry revealed osteopenia: T score =?1.71±0.91; Ward score=?2.22±0.917; BMD (bone density) =0.879±0.126. The second bone densitometry showed progression to osteoporosis and a significant 6% reduction of the BMD: T Score=?1.95±0.84; Ward score=?2.4±0.87; BMD=0.819±0.12. During this time interval, 3 patients developed a fracture of the femur and a fourth patient fractured two ribs after physical exertion. All patients compalined of decreased physical strength and very marked fatigability. We can conclude that androgen suppression causes an alteration of locomotor function and quality of life of patients treated for prostate cancer and presenting a long life expectancy.     

Ultrastructure of ulvan: A polysaccharide from green seaweeds

Ultrastructural analysis of the gel forming green seaweed sulfated polysaccharide ulvan revealed a spherical‐based morphology (10–18 nm diameter) more or less aggregated in aqueous solution. At pH 13 in TBAOH (tetrabutyl ammonium hydroxyde) or NaOH, ulvan formed an open gel‐like structure or a continuous film by fusion or coalescence of bead‐like structures, while in acidic pH conditions, ulvan appeared as dispersed beads. Low concentrations of sodium chloride, copper or boric acid induced the formation of aggregates. These results highlight the hydrophobic and aggregative behavior of ulvan that are discussed in regard to the peculiar gel formation and the low intrinsic viscosity of the polysaccharide in aqueous solution. © 2009 Wiley Periodicals, Inc. Biopolymers 91: 652–664, 2009. This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com     

Use of Uteroglobin for the Engineering of Polyvalent, Polyspecific Fusion Proteins

We report a novel strategy to engineer and express stable and soluble human recombinant polyvalent/polyspecific fusion proteins. The procedure is based on the use of a central skeleton of uteroglobin, a small and very soluble covalently linked homodimeric protein that is very resistant to proteolytic enzymes and to pH variations. Using a human recombinant antibody (scFv) specific for the angiogenesis marker domain B of fibronectin, interleukin 2, and an scFv able to neutralize tumor necrosis factor-α, we expressed various biologically active uteroglobin fusion proteins. The results demonstrate the possibility to generate monospecific divalent and tetravalent antibodies, immunocytokines, and dual specificity tetravalent antibodies. Furthermore, compared with similar fusion proteins in which uteroglobin was not used, the use of uteroglobin improved properties of solubility and stability. Indeed, in the reported cases it was possible to vacuum dry and reconstitute the proteins without any aggregation or loss in protein and biological activity.The generation of recombinant polyvalent and/or polyspecific fusion proteins for use as components of novel drugs is still hindered by factors that limit their production, storage, and use, chief of which are issues related to instability and/or inadequate solubility. Here we describe a novel approach based on the use of uteroglobin (UG)³ as a skeleton for the generation of polyvalent/polyspecific recombinant proteins. Human UG is a small (15.8 kDa) globular, nonglycosylated, and homodimeric secreted protein that was discovered independently by two groups in the 1960s in rabbit uterus (1, 2), and it is the first member of a new superfamily of proteins, the so-called Secretoglobins (Scgb) (3). UG is present in the blood at a concentration of about 15 μg/ml and is found in urine and in other body fluids. The UG monomer is composed of about 70 amino acids, depending on the species, and is organized in a four α-helix secondary structure; the two subunits are joined in an anti-parallel fashion by disulfide bridges established between two highly conserved cysteine residues in amino- and carboxyl-terminal positions (4) (see Fig. 1). The exact functions of UG are not yet clear, but the protein has been reported to have anti-inflammatory properties due to its ability to inhibit the soluble phospholipase A₂. Moreover, UG contains a central hydrophobic cavity able to accommodate hydrophobic molecules such as progesterone, retinol, and prostaglandin D₂. Theoretically, this cavity could be loaded with different types of therapeutic hydrophobic substances and delivered to targets (for exhaustive reviews on UG, see Refs. 5, 6 and references therein).Open in a separate windowFIGURE 1.Central part of the figure depicts the ribbon structure of the oxidized homodimer of UG (adapted with permission from Ref. 4). A–E show the schemes of the various fusion proteins produced using UG as a central core. L19 is an scFv specific for the angiogenesis-associated FN isoform, and D2E7 is an scFv able to neutralize TNF-α.The high solubility and stability of UG to pH and temperature variations, its resistance to proteases, and its homodimeric structure prompted us to consider the protein as a candidate linker for the generation of polyvalent and polyspecific recombinant proteins. We demonstrate here that the use of UG as a linker could provide a general method for the generation of covalently linked bivalent and tetravalent antibodies, either monospecific or bispecific, as well as of different kinds of fusion proteins, which, compared with similar fusion proteins without UG, possess generally enhanced properties of solubility and stability, factors that expedite their storage and clinical use.We describe the use of UG for the production of a bivalent and tetravalent format of L19, an scFv specific for the angiogenesis-associated extra domain B (ED-B) of fibronectin (FN) (7), of an immunocytokine composed of IL2 and L19, and of a tetravalent dual specificity antibody composed of L19 and the scFv D2E7, a human antibody able to neutralize TNF-α activity (8). We report and discuss the characterization, properties, and the biological activity, both in vitro and in vivo, of these molecules.     

An investigation of the occurrence and properties of the mitochondrial intermediate-conductance Ca2+-activated K+ channel mtKCa3.1

The mitochondrial intermediate-conductance Ca²⁺-activated K⁺ channel mtK_Ca3.1 has recently been discovered in the HCT116 colon tumor-derived cell line, which expresses relatively high levels of this protein also in the plasma membrane. Electrophysiological recordings revealed that the channel can exhibit different conductance states and kinetic modes, which we tentatively ascribe to post-translational modifications. To verify whether the localization of this channel in mitochondria might be a peculiarity of these cells or a more widespread feature we have checked for the presence of mtK_Ca3.1 in a few other cell lines using biochemical and electrophysiological approaches. It turned out to be present at least in some of the cells investigated. Functional assays explored the possibility that mtK_Ca3.1 might be involved in cell proliferation or play a role similar to that of the Shaker-type K_V1.3 channel in lymphocytes, which interacts with outer mitochondrial membrane-inserted Bax thereby promoting apoptosis (Szabò, I. et al., Proc. Natl. Acad Sci. USA 105 (2008) 14861–14866). A specific K_Ca3.1 inhibitor however did not have any detectable effect on cell proliferation or death.     

Prevalence of C282Y and H63D mutations in the haemochromatosis (HFE) gene in Tunisian population

The studies of the HFE mutations: H63D and C282Y in North African populations have revealed the extreme rarity or even the absence of the C282Y mutation. We have examined 1140 chromosomes (570 Tunisian people) for the presence of the two HFE mutations by PCR-RFLP analysis. We have found that the allele frequencies are, respectively, 15.17% (+/-2.1%) for the H63D and 0.09% (+/-0.17%) for the C282Y. These results are consistent with the worldwide spread of the H63D mutation and the north European restriction of the C282Y. This study will be completed by determining whether homozygote trait for H63D and associated risk factors (beta thalassémia) can lead to iron overload in Tunisia.     

Synthesis,characterization and X-ray structures of new antiproliferative and proapoptotic natural aldehyde thiosemicarbazones and their nickel(II) and copper(II) complexes

Synthesis and characterization of new thiosemicarbazones derived from natural aldehydes (1–9) have been investigated in order to develop a research program aimed at the development of compounds with antiviral, antibacterial, and antitumor properties. These substances contain both a chain with N and S nucleophilic centers with tuberculostatic activity, and an alkyl or terpenic moiety. In addition, a few nickel(II) and copper(II) complexes (10–18), derived also from the previously studied ligands, were synthesized and characterized by means of NMR and IR techniques. The trans-2-octenal N¹-phenylthiosemicarbazone and its nickel complex were also characterized by X-ray diffractometry. Biological studies, performed with some of these compounds, have involved both inhibition of cell proliferation and apoptosis tests in vitro on human leukemia cell line U937 to deepen our knowledge on the way these substances interfere with biological processes in leukemic cells.